Abstract:Background: Mammalian cell lines are frequently used as protein expression hosts because of their ability to correctly fold and assemble complex proteins, produce them at high titers, and confer post-translational modifications (PTMs) critical to proper function. Increasing demand for proteins with human-like PTMs, particularly viral proteins and vectors, have made human embryonic kidney 293 (HEK293) cells an increasingly popular host. The need to engineer more productive HEK293 platforms and the ongoing nature of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic presented an opportunity to study strategies to improve viral protein expression in transient and stable HEK293 platforms. Results: Initial process development was done at 24 deep well plate (DWP) -scale to screen transient processes and stable clonal cell lines for recombinant SARS-CoV-2 receptor binding domain (rRBD) titer. Nine DNA vectors that drove rRBD production under different promoters and optionally contained Epstein-Barr virus (EBV) elements to promote episomal expression were screened for transient rRBD production at 37 °C or 32 °C. Use of the cytomegalovirus (CMV) promoter to drive expression at 32 °C led to the highest transient protein titers, but inclusion of episomal expression elements did not augment titer. In parallel, four clonal cell lines with titers higher than that of the selected stable pool were identified in a batch screen. Flask-scale transient transfection and stable fed-batch processes were then established that produced rRBD up to 100 mg/L and 140 mg/L, respectively. While a bio-layer interferometry (BLI) assay was crucial for efficiently screening DWP batch titers, an enzyme-linked immunosorbent assay (ELISA) was used to compare titers from the flask-scale batches due to varying matrix effects from different cell culture media compositions. Conclusion: Comparing yields from the flask-scale batches revealed that stable fed-batch cultures produced up to 2.1x more rRBD than transient processes. The stable cell lines developed in this work are the first reported clonal, HEK293-derived rRBD producers and have titers up to 140 mg/L. As stable production platforms are more economically favorable for long-term protein production at large scales, investigation of strategies to increase the efficiency of high-titer stable cell line generation in Expi293F or other HEK293 hosts is warranted.

The Scattered Twelve Tribes of HEK293

HEK293 Cell Line as a Platform to Produce Recombinant Proteins and Viral Vectors

Current strategies for the development of high-yield HEK293 cell lines

Affecting HEK293 Cell Growth and Production Performance by Modifying the Expression of Specific Genes

[Progress in the Derivation, Culture of Human Embryonic Stem Cells].

Evolution from adherent to suspension: systems biology of HEK293 cell line development

Protocol for cell preparation and gene delivery in HEK293T and C2C12 cells

HEK-Omics: The promise of omics to optimize HEK293 for recombinant adeno-associated virus (rAAV) gene therapy manufacturing

Comprehensive mRNA‐sequencing‐based characterization of three HEK‐293 cell lines during an rAAV production process for Gene Therapy Applications

Construction of a stable expression HEK293T engineered cell line adapted to high-density suspension culture

Comparison of vector elements and process conditions in transient and stable suspension HEK293 platforms using SARS-CoV-2 receptor binding domain as a model protein

An optimized HEK293T cell expansion protocol using a hollow-fiber bioreactor system

Process Optimization for the Rapid Production of Adenoviral Vectors for Clinical Trials in a Disposable Bioreactor System.

An anti-apoptotic HEK293 cell line provides a robust and high titer platform for transient protein expression in bioreactors

Protein production from HEK293 cell line-derived stable pools with high protein quality and quantity to support discovery research

Comprehensive Analysis of Genomic Safe Harbors as Target Sites for Stable Expression of the Heterologous Gene in HEK293 Cells.

Development of a laboratory scalable process for enhancing lentivirus production by transient transfection of HEK293 adherent cultures

Small-Scale Cultivation and Transfection of ExpiCHO and HEK293E Cells in Single-Use Orbitally Shaken Bioreactors

A Streamlined and Standardized Procedure for Generating High-Titer, High-Quality Adeno-Associated Virus Vectors Utilizing a Cell Factory Platform

A new T‐antigen negative HEK293 cell line with improved AAV productivity

Improvement strategies for transient gene expression in mammalian cells